CUE BIOPHARMA INC's ticker is CUE and the CUSIP is 22978P106. A total of 94 filers reported holding CUE BIOPHARMA INC in Q3 2020. The put-call ratio across all filers is 0.71 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,100,550 | -37.0% | 478,500 | 0.0% | 0.07% | -40.3% |
| Q2 2023 | $1,746,525 | +2.2% | 478,500 | 0.0% | 0.12% | -5.3% |
| Q1 2023 | $1,708,245 | +25.3% | 478,500 | 0.0% | 0.13% | -1.5% |
| Q4 2022 | $1,363,725 | +27.8% | 478,500 | 0.0% | 0.13% | +19.8% |
| Q3 2022 | $1,067,000 | -10.4% | 478,500 | 0.0% | 0.11% | -0.9% |
| Q2 2022 | $1,191,000 | -49.0% | 478,500 | 0.0% | 0.11% | -42.9% |
| Q1 2022 | $2,335,000 | -56.8% | 478,500 | 0.0% | 0.20% | -56.9% |
| Q4 2021 | $5,411,000 | -22.4% | 478,500 | 0.0% | 0.46% | -42.2% |
| Q3 2021 | $6,971,000 | +25.1% | 478,500 | 0.0% | 0.79% | +17.6% |
| Q2 2021 | $5,574,000 | -4.5% | 478,500 | 0.0% | 0.67% | -28.4% |
| Q1 2021 | $5,837,000 | -3.6% | 478,500 | -1.1% | 0.93% | -26.2% |
| Q4 2020 | $6,054,000 | -16.9% | 484,000 | 0.0% | 1.26% | -29.3% |
| Q3 2020 | $7,284,000 | – | 484,000 | – | 1.79% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Prosight Management, LP | 1,510,282 | $7,370,000 | 4.76% |
| SANDERS MORRIS HARRIS LLC | 873,021 | $4,261,000 | 0.83% |
| P.A.W. CAPITAL CORP | 150,000 | $732,000 | 0.76% |
| Nantahala Capital Management | 2,244,359 | $10,952,000 | 0.48% |
| Bleichroeder LP | 552,000 | $2,694,000 | 0.48% |
| APOGEM CAPITAL LLC | 111,259 | $543,000 | 0.37% |
| Slate Path Capital LP | 1,483,619 | $7,240,000 | 0.37% |
| Robertson Stephens Wealth Management, LLC | 478,500 | $2,335,000 | 0.20% |
| CARLSON CAPITAL L P | 405,000 | $1,976,000 | 0.14% |
| Bridgefront Capital, LLC | 19,968 | $97,000 | 0.12% |